If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end Q2, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship wi ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortrea Holdings, Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 25-cv-04630, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fortrea securities between July 3, 2023 and February 28, ...

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group Plc, alleging securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves allegations against Reckitt and certain officers and directors for engaging in securities fraud or other unlawful business practices [2]. - Investors have until August 4, 2025, to request to be appointed as Lead Plaintiff if they purchased Reckitt securities during the Class Period [2]. Group 2: Financial Impact - On March 15, 2024, Reckitt's American Depositary Share (ADS) price fell by $1.87, nearly 14%, closing at $11.44 following a $60 million verdict against its Mead Johnson subsidiary for negligence related to infant formula [3][4]. - On July 29, 2024, after a similar lawsuit against Abbott Laboratories, Reckitt's ADS price dropped by $1.02, nearly 9%, closing at $10.64 [4]. Group 3: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [5].

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Organon and certain of its officers and/or d ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. ("DoubleVerify" or the "Company")(NYSE: DV). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether DoubleVerify and certain of ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Schrödinger and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On May 20, 2025, Sc ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 30, 2025, Sanofi issued a pres ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ: QIPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Quipt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On June 5, 2025, Forag ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc. ("NWTN" or the "Company") (NASDAQ: NWTN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether NWTN and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 28, 2025, NWTN disclosed receipt ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Laser Photonics Corporation ("Laser Photonics" or the "Company") (NASDAQ: LASE).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Laser Photonics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class actio ...